Hermes Medical Solutions Enhances Molecular Imaging for Personalized Patient Care
Stockholm, Monday, 17 March 2025.
Hermes Medical Solutions’ latest Hermia software accelerates diagnosis and personalizes therapy, enhancing patient outcomes in a vendor-neutral environment.
Revolutionary Integration in Nuclear Medicine
The Hermia software platform represents a significant advancement in nuclear medicine workflow, enabling seamless connectivity across all equipment and staff in a vendor-neutral environment [1]. This integration is particularly crucial for nuclear medicine departments, where the software has demonstrated measurable improvements in test reading efficiency, as evidenced by implementation at the Centre Hospitalier de l’Université de Montréal’s Nuclear Medicine department [1].
Educational Impact and Global Reach
The system’s educational integration is exemplified through the Hermia Academy site at the British Columbia Institute of Technology (BCIT), where nuclear medicine students receive hands-on training with the software [1]. The company’s reach continues to expand, with significant growth in partnerships across the USA, Europe, and Asia-Pacific regions [2]. A notable milestone includes the achievement of EARL Theranostic certification, validating the platform’s expertise in nuclear medicine applications [2].
Clinical Implementation and Future Outlook
The platform’s clinical impact is set to expand significantly, with projections indicating an increase in outpatient capacity from 2-3 patients per week to 10-15 by the end of 2025 [2]. The system’s capabilities are particularly relevant for advanced medical imaging applications, as demonstrated in recent research utilizing total-body PET/CT imaging [3]. An upcoming showcase of the platform’s capabilities is scheduled for the JOURNÉES FRANCOPHONES DE MÉDECINE NUCLÉAIRE (JFMN) from March 20-22, 2025, in Paris [1], where healthcare professionals will examine the latest developments in nuclear medicine and molecular imaging.